Patient participation
. | Treatment group . | . | . | |
---|---|---|---|---|
. | PCT, n (%) n = 318 . | Control, n (%) n = 327 . | P . | |
Completed transfusion period | 280 (88) | 294 (90) | .53 | |
Reason for not completing transfusion period | ||||
Patient decided to withdraw | 8 (2.5) | 4 (1.2) | .26 | |
Physician withdrew patient | 10 (3.1) | 4 (1.2) | .11 | |
Adverse event(s) | 0 (0) | 0 (0) | — | |
Lost to follow-up | 1 (< 1) | 1 (< 1) | — | |
Death | 10 (3.1) | 15 (4.6) | .42 | |
Other | 9 (2.8) | 9 (2.8) | — | |
Total | 38 (11.9) | 33 (10.1) | .44 | |
Mean days of platelet support | 11.8 | 10.6 | .08 | |
Achieved and maintained platelet independence prior to day 28 | 210 (66) | 230 (70) | .27 | |
Completed surveillance period | 248 (78) | 273 (84) | .09 |
. | Treatment group . | . | . | |
---|---|---|---|---|
. | PCT, n (%) n = 318 . | Control, n (%) n = 327 . | P . | |
Completed transfusion period | 280 (88) | 294 (90) | .53 | |
Reason for not completing transfusion period | ||||
Patient decided to withdraw | 8 (2.5) | 4 (1.2) | .26 | |
Physician withdrew patient | 10 (3.1) | 4 (1.2) | .11 | |
Adverse event(s) | 0 (0) | 0 (0) | — | |
Lost to follow-up | 1 (< 1) | 1 (< 1) | — | |
Death | 10 (3.1) | 15 (4.6) | .42 | |
Other | 9 (2.8) | 9 (2.8) | — | |
Total | 38 (11.9) | 33 (10.1) | .44 | |
Mean days of platelet support | 11.8 | 10.6 | .08 | |
Achieved and maintained platelet independence prior to day 28 | 210 (66) | 230 (70) | .27 | |
Completed surveillance period | 248 (78) | 273 (84) | .09 |
— indicates not applicable.